Eloctate (Antihemophilic factor - rFVIIIFc)

Eloctate and Elocta (European name) are stable at room temperature for 6 months.  

Save up to 60% on Elocta - the European version of Eloctate.

Non-english packaging is often present for European medicines- English label and English insert included. Plan in advance - allow us 7 days to ship this brand name medicine.

According to the European Medicines Agency, brand name Elocta originating from Europe is manufactured at the following site(s):Swedish Orphan Biovitrum AB (publ) SE-112 76 Stockholm Sweden

Information about Eloctate (Antihemophilic Factor - rFVIIIFc)

Eloctate is a recombinant version of the clotting factor VIII (rFVIIIFc), designed for the treatment and prophylaxis of bleeding episodes in individuals with hemophilia A, a genetic disorder where the blood does not clot properly due to a deficiency in clotting factor VIII. Eloctate is a long-acting treatment developed using recombinant DNA technology to replace the missing clotting factor and is specifically designed to prolong the half-life of factor VIII, enabling less frequent dosing.

Product Highlights

• Eloctate is primarily indicated for the treatment and prevention of bleeding episodes in patients with hemophilia A, including both adults and pediatric patients.
• It is also indicated for routine prophylactic treatment to reduce the frequency of bleeding episodes, and to prevent or reduce the severity of bleeds, particularly in patients with moderate to severe hemophilia A.

Key Ingredient

• Recombinant Antihemophilic Factor - rFVIIIFc (Eloctate)

Key Benefits

• Eloctate has a significantly longer half-life compared to traditional factor VIII concentrates, meaning fewer infusions are needed over time. This results in a reduced treatment burden.
• By requiring less frequent dosing, Eloctate helps improve the daily life of individuals with hemophilia A, reducing hospital visits and allowing for more flexibility.
• Eloctate is effective in both treating acute bleeding episodes and preventing bleeds from occurring in the first place (prophylaxis), especially for those with severe hemophilia A.
• As a recombinant product, Eloctate carries a lower risk of viral transmission compared to products derived from human plasma.

Direction of Use

• Eloctate is administered via intravenous (IV) infusion. The specific dosing schedule is determined by the treating physician based on the patient’s individual needs and response to treatment.
• For patients on prophylaxis, Eloctate is typically infused every 3 to 5 days to maintain adequate factor VIII levels and prevent bleeding episodes.
• In cases of bleeding, Eloctate is infused at higher doses as needed to control the episode, depending on the severity and location of the bleed.
• Patients and caregivers must be trained to properly administer the IV infusion. In some cases, patients may self-administer the infusion at home under the supervision of their healthcare provider.

Safety Concerns

• Like other factor VIII products, Eloctate can cause allergic reactions, including anaphylaxis in rare cases. Symptoms may include rash, hives, difficulty breathing, or swelling, and medical attention should be sought immediately if these occur.
• Some patients with hemophilia A may develop inhibitors (antibodies) to factor VIII, which can reduce the effectiveness of the treatment and increase the risk of bleeding. Regular monitoring of factor VIII activity and inhibitor development is essential.
• The use of factor VIII products, including Eloctate, has been associated with an increased risk of thrombosis (blood clots), especially if used at higher doses or in patients with existing risk factors for clotting disorders.
• While Eloctate is produced using recombinant technology and carries a very low risk of infection, it is still essential for patients to follow proper infusion practices to minimize infection risk at the injection site.

Avoid Eloctate (Antihemophilic Factor - rFVIIIFc) If

• Patients who are allergic to any component of Eloctate should not use the product. Hypersensitivity reactions, including anaphylaxis, have been reported in some individuals.
• Eloctate should be avoided if a patient has a history of developing inhibitors to factor VIII, or if the patient is known to have an existing inhibitor, as this may reduce the efficacy of treatment.
• Caution is required when using Eloctate in patients with severe liver dysfunction, as liver function may affect the metabolism and clearance of factor VIII products.
• Eloctate should be used cautiously or avoided in patients with a history of thrombosis (clots) or those who are at high risk for clotting disorders, as it may increase the risk of thromboembolic events.